Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455579 | 1.00 | MGMT (0.39) | MGMTMGLLCA12CA1CA2 | |
| SCHEMBL30459733 | 1.00 | MGMT (0.39) | MGMTMGLLCA12CA1CA2 | |
| SCHEMBL25495612 | 0.86 | MGMT (0.42) | MGMTMGLLABCG2 | |
| SCHEMBL17262434 | 0.84 | MGMT (0.40) | MGMTMGLLABCG2 | |
| SCHEMBL30458078 | 0.82 | MGMT (0.42) | MGMTMGLLCA12CA1CA2 | |
| SCHEMBL26349179 | 0.82 | MGMT (0.42) | MGMTMGLLCA12CA1CA2 | |
| SCHEMBL28194378 | 0.82 | MGLL (0.43) | MGLLCA12CA1CA2CA4 | |
| SCHEMBL18212282 | 0.78 | MGMT (0.40) | MGMTMGLLABCG2 | |
| SCHEMBL26349168 | 0.78 | MGMT (0.43) | MGMTMGLLABCG2 | |
| SCHEMBL29199650 | 0.77 | HPGD (0.49) | MGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | CYP3A43, CYP2C9, CYP2C19 | MGMT 2441/4885MGLL 2029/4885CA12 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.